BRAF inhibitors combined with MEK inhibitors have shown promising potential as neoadjuvant therapy in other tumors, such as locally advanced melanoma or metastatic thyroid cancer; however, the evidence in patients with NSCLC remains very limited (23, 24). This evidence concerns the gene MAP2K7 and melanoma.